Shares of Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) dropped 1.2% during mid-day trading on Friday . The company traded as low as $7.2250 and last traded at $7.47. Approximately 66,556 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 842,200 shares. The stock had previously closed at $7.56.
Ampliphi Biosciences Stock Down 1.2%
The business has a 50 day moving average price of $9.68 and a 200-day moving average price of $8.35.
Ampliphi Biosciences Company Profile
Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.
The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.
Featured Stories
- Five stocks we like better than Ampliphi Biosciences
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
